Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 5/20 | 0.49 |
| ▸ | MET | P08581 | 5/20 | 0.48 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090591 | 0.89 | MET (0.57) | RBP4METHMOX1MAPK1DPP4 | |
| SCHEMBL4090074 | 0.79 | CTSS (0.66) | CTSS | |
| SCHEMBL4085097 | 0.79 | CTSS (0.63) | CTSS | |
| SCHEMBL4091516 | 0.79 | CTSS (0.66) | CTSS | |
| SCHEMBL4091664 | 0.78 | CTSS (0.62) | CTSS | |
| SCHEMBL4094746 | 0.78 | CTSS (0.62) | CTSS | |
| SCHEMBL13845951 | 0.78 | CTSS (0.62) | CTSS | |
| SCHEMBL4079471 | 0.78 | CTSS (0.65) | CTSS | |
| SCHEMBL4089147 | 0.78 | CTSS (0.61) | CTSS | |
| SCHEMBL5257069 | 0.77 | MAPK1 (0.63) | RBP4METHMOX1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118274-A1 | MONOCYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | RBP4 3080/4885MET 4449/4885HMOX1 2517/4885 |
| US-20090118274-A1 | MONOCYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | RBP4 3546/4885MET 3516/4885HMOX1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.